Cargando…
The scientific basis for novel treatments of systemic sclerosis
In recent years, many potential antifibrotic treatment strategies have emerged from molecular studies of systemic sclerosis. Few biologicals have already entered clinical trials and these may hopefully prove to be effective in this progressive, profibrotic disease.
Autores principales: | Beyer, Christian, Distler, Jörg HW |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948335/ https://www.ncbi.nlm.nih.gov/pubmed/20948682 http://dx.doi.org/10.3410/M1-95 |
Ejemplares similares
-
Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
por: Beyer, Christian, et al.
Publicado: (2009) -
A broad look into the future of systemic
sclerosis
por: Riemekasten, Gabriela, et al.
Publicado: (2022) -
Vascular alterations upon activation of TGFβ signaling in fibroblasts - implications for systemic sclerosis
por: Horn, Angelika, et al.
Publicado: (2010) -
The scientific basis of multiple sclerosis
por: Cuzner, M.Louise, et al.
Publicado: (1979) -
Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)